2076975 2077203
최종편집 2020-08-08 11:59 (토)
Eisai Korea made annual sales of $200 billion and an operating profit of $30 billion
상태바
Eisai Korea made annual sales of $200 billion and an operating profit of $30 billion
  • Heokgi Lee, Newsmp
  • 승인 2020.07.22 13:56
  • 댓글 0
이 기사를 공유합니다

Expands the rate of operating profits by 15%... during a slowdown in the growth of sales

Eisai Korea (CEO Ko Hong-Byung)’s annual sales exceeded $200 billion. Operating profit, which has been steadily increasing along with sales, also surpassed $30 billion.

According to Eisai’s report of audit (June 30th), Eisai Korea made $209.6 billion in annual sales.

Eisai Korea recorded steady growth for the past three years since 2016 and made about $200 billion sales in 2018 by expanding insurance coverage of drugs with Lenvima, Symbenda, Tysabri, and Tecfidera.

▲ Annual sales of Eisai Korea ; Eisai Korea’s annual sales exceeded $200 billion.
▲ Annual sales of Eisai Korea ; Eisai Korea’s annual sales exceeded $200 billion.

Although Eisai Korea surpassed $200 billion by expanding its sales by $10 billion, the growth slowed significantly to 5.9 %.

The growth was stagnant, but the operating profits constantly exceeded $30 billion, and the rate of operating profits have risen to 15%.

▲ Annual rate of operating profits of Eisai Korea ; Operating profit, which has been steadily increasing along with sales, also surpassed $30 billion.
▲ Annual rate of operating profits of Eisai Korea ; Operating profit, which has been steadily increasing along with sales, also surpassed $30 billion.

Eisai Korea’s operating profit fell slightly from $16.1 billion in 2015 to $15.9 billion in 2016 but increased sharply thereafter.

The operating profit surpassed $20 billion in 2017 with $23.6 billion and exceeded $32 billion in 2019 from $29 billion in 2018. The size of the operating profit has doubled in about four years.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.